Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma (GLIO-XS15)

  • End date
    May 2, 2024
  • participants needed
  • sponsor
    University Hospital Tuebingen
Updated on 26 May 2022


Newly diagnosed HLA-A2-positive MGMT-methylated glioblastoma patients will be vaccinated with a Multi peptide vaccination with Pam3Cys-GDPKHPKSF (XS15) as an immunomodulator in addition to standard postoperative radiation therapy and temozolomide chemotherapy to assess immunogenicity, efficacy, safety of the combination of multipeptide vaccination and the immune modulator XS15 emulsified in Montanide ISA 51 VG

Condition Glioblastoma Multiforme of Brain
Treatment Multipeptide plus XS15
Clinical Study IdentifierNCT04842513
SponsorUniversity Hospital Tuebingen
Last Modified on26 May 2022


Yes No Not Sure

Inclusion Criteria

Subjects meeting all of the following criteria will be considered for admission to the
For screening phase: (Consent C1)
Must be ≥ 18 years at the time of signing the informed consent 2. Suspected Glioblastoma (presenting with a MRI suggestive of glioblastoma and eligible for gross or subtotal resection and standard radiotherapy with temozolomide) For Vaccination phase (Consent C2)
Histologically confirmed, newly diagnosed IDH1-wildtype glioblastoma (astrocytoma WHO grade IV)
MGMT gene promoter methylation
HLA phenotype HLA-A02:01 (as determined by a PCR-based 4-digit typing method)
Gross or subtotal resection (20%, as determined by MRI)
Postoperative MRI
KPS ≥70%
Life expectancy > 6 months
Patient is a candidate for and willing to receive standard radiation therapy with TMZ followed by maintenance TMZ cycles
Patient is not on steroids or on stable or decreasing steroid levels not exceeding 2 mg/day dexamethasone (or equivalent doses of other steroids) during the last 3 days prior to first dose of IMP (Vaccination 1)
Absolute lymphocyte count (ALC) >0.5 x109/L (re-screening of lymphocyte counts is allowed at day of vaccination)
Ability of subject to understand and the willingness to sign written informed consent for study participation prior to any study related assessments/procedures. Able to adhere to the study visit schedule and other protocol requirements
Female Patient of childbearing potential1 and male patients with female partner of childbearing potential1 is willing to use highly effective contraceptive methods during treatment and for 30 days after the end of treatment. According to the CTFG Recommendations highly effective contraceptive methods are
combined hormonal contraceptive associated with inhibition of ovulation (oral,-intravaginal,-transdermal)
progestogen-only hormonal contraception associated with inhibition of ovulation (pral injectable, implantable)
intrauterine device (IUD)
intrauterine hormone-releasing system (IUS)
bilateral tubal occlusion
vasectomized partner2
sexual abstinence3
Negative Covid 19 Quick Test
Female subjects must abstain from breastfeeding during study participation and 30 days after study drug discontinuation
Male subjects must refrain from donating semen or sperm while on study
All subjects must agree to refrain from donating blood while on study drug and for 30 days after discontinuation from this study treatment
All subjects must agree not to share medication

Exclusion Criteria

Subjects presenting with any of the following criteria will not be included in the
Karnofsky performance score (KPS) < 70%
Patient who cannot undergo MRI assessments
Only Biopsy available
Women during pregnancy and lactation
History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
Participation in other clinical trials or observation period of competing trials
Platelet count decrease < 75 x109/L
Bilirubin > 1.5 x ULN (upper limit of normal according to the performing lab's reference range)
ALT4 > 3 x ULN
AST5 > 3 x ULN
GGT > 2.5 x ULN
Serum creatinine increased > 1.5 x ULN
HIV infection or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or that can cause a severe disease and pose a severe danger to lab personnel working on patients' blood or tissue (e.g. rabies)
Prior therapy for glioma (except surgery and steroids) including but not limited to carmustine wafers and immunotherapy. Note: History of low grade glioma that did not require prior treatment with chemotherapy or radiotherapy is not an exclusion criterion
Clinically relevant autoimmune diseases (with the exception of thyroid diseases)
Immunosuppression, not related to prior treatment for malignancy, or prior drug reaction
Other vaccinations with active or attenuated viruses should be restricted during the peptide vaccination period
Enzyme-inducing antiepileptic drugs
Patients with prior stem cell transplantation or solid organ transplantation
Any condition that in the judgment of the investigator interferes with the probability that an individual patient may receive and benefit from APVAC vaccinations (e.g. high risk of early disease progression / recurrence; immunocompromised status; anticipated compliance problems)
Serious illness or condition, which according to the investigator, poses an undue risk for the patient when participating in the trial, including, but not limited to, any of the following
Clinically symptomatic cardiovascular disease:(New York Heart Association class III-IV congestive heart failure)
Symptomatic peripheral vascular disease (Definition z.B. > Stage III)
Severe pulmonary dysfunction (Definition: z.B. requirement for oxygen supplement
Severe diabetes
History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 5 years unless the patient has been disease-free for 5 years
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note